MA56550A - Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation - Google Patents

Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation

Info

Publication number
MA56550A
MA56550A MA056550A MA56550A MA56550A MA 56550 A MA56550 A MA 56550A MA 056550 A MA056550 A MA 056550A MA 56550 A MA56550 A MA 56550A MA 56550 A MA56550 A MA 56550A
Authority
MA
Morocco
Prior art keywords
diazaspiro
octane
carboxylate
oxo
tert
Prior art date
Application number
MA056550A
Other languages
English (en)
Inventor
Danny T Ding
Shaoxin Feng
William R Perrault
Xiaoda Yuan
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of MA56550A publication Critical patent/MA56550A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA056550A 2019-06-24 2020-06-23 Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation MA56550A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962865826P 2019-06-24 2019-06-24

Publications (1)

Publication Number Publication Date
MA56550A true MA56550A (fr) 2022-04-27

Family

ID=74060350

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056550A MA56550A (fr) 2019-06-24 2020-06-23 Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation

Country Status (12)

Country Link
US (1) US20220267341A1 (fr)
EP (1) EP3986399A4 (fr)
JP (2) JP7617043B2 (fr)
KR (1) KR20220061088A (fr)
CN (1) CN114364380A (fr)
AU (1) AU2020304001A1 (fr)
BR (1) BR112021026380A2 (fr)
CA (1) CA3144600A1 (fr)
IL (1) IL289198A (fr)
MA (1) MA56550A (fr)
MX (2) MX2022000069A (fr)
WO (1) WO2020263847A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56551A (fr) * 2019-06-24 2022-04-27 Naurex Inc Procédés et intermédiaires pour la production de composés de diazaspiro-lactame

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
CN102503899B (zh) * 2005-06-21 2014-09-24 味之素株式会社 苯基丙氨酸衍生物的结晶、其制备方法及其应用
KR101769999B1 (ko) * 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Ｎｍｄａ 수용체 조절제 및 그의 용도
SI2951183T1 (sl) * 2013-01-29 2019-07-31 Aptinyx Inc. Spiro-laktam NMDA receptorski modulatorji in njihove uporabe
WO2014120786A1 (fr) * 2013-01-29 2014-08-07 Naurex, Inc. Modulateurs spirolactames d'un récepteur nmda et leurs utilisations
DK3436463T3 (da) * 2016-03-28 2021-08-30 Takeda Pharmaceuticals Co Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat
WO2017201283A1 (fr) * 2016-05-19 2017-11-23 Aptinyx Inc. Modulateurs de récepteurs nmda de spiro-lactame et utilisations associées
MA56551A (fr) * 2019-06-24 2022-04-27 Naurex Inc Procédés et intermédiaires pour la production de composés de diazaspiro-lactame

Also Published As

Publication number Publication date
JP2022539342A (ja) 2022-09-08
CA3144600A1 (fr) 2020-12-30
KR20220061088A (ko) 2022-05-12
BR112021026380A2 (pt) 2022-05-10
IL289198A (en) 2022-02-01
JP2025069143A (ja) 2025-04-30
CN114364380A (zh) 2022-04-15
AU2020304001A1 (en) 2022-01-27
JP7617043B2 (ja) 2025-01-17
US20220267341A1 (en) 2022-08-25
WO2020263847A1 (fr) 2020-12-30
MX2025002579A (es) 2025-04-02
MX2022000069A (es) 2022-05-24
EP3986399A1 (fr) 2022-04-27
EP3986399A4 (fr) 2023-06-07

Similar Documents

Publication Publication Date Title
EP3934652A4 (fr) Composés, compositions et procédés pour le traitement d'une maladie
EP3980046A4 (fr) Mutant g12v de kras se liant à jak1, inhibiteurs, compositions pharmaceutiques et procédés associés
PH12020551352A1 (en) Arginase inhibitors
MX2019013954A (es) Inhibidores covalentes de kras.
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
EP3914651A4 (fr) Compositions d'agrégats de carbonate et leurs procédés de préparation et d'utilisation
EP2663309A4 (fr) Procédés de préparation d'isoquinolinones et de formes solides d'isoquinolinones
EP3504196A4 (fr) Procédés de préparation d'olaparib
WO2016164675A8 (fr) Composés quinazoline substitués et leurs procédés d'utilisation
WO2015200680A8 (fr) Inhibiteurs de prmt5 et leurs utilisations
MX380928B (es) Inhibidores de kras g12c.
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
EP3359159A4 (fr) Sels pharmaceutiques, formes physiques, et compositions d'inhibiteurs pyrrolopyrimidine de kinases, et leurs procédés de préparation
EP3969457A4 (fr) Procédés de préparation d'indoles macrocycliques
PH12018500653B1 (en) Salts and solid forms of monobactam antibiotic
EP3893655A4 (fr) Procédés pour la préparation d'un composition de protéines végétales
MA53427B1 (fr) Inhibiteurs de l'arginase et leurs méthodes d'utilisation
MA56550A (fr) Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation
WO2017095950A3 (fr) Composés pour traiter des maladies prolifératives
MA50862A (fr) Procédés de réduction des effets secondaires d'une thérapie par conjugués médicament anticorps anti-cd30
EP3411359A4 (fr) Procédés de préparation de dérivés d'hydroxylamine utiles dans la préparation d'agents anti-infectieux
EP4031130A4 (fr) Compositions pour le traitement de tumeurs solides
EP3445370A4 (fr) Procédés de préparation d'acide obéticholique et de dérivés de celui-ci
MA53603A (fr) Procédés de modulation de la cytotoxicité à médiation cellulaire dépendante des anticorps
EP3314001A4 (fr) Procédés et compositions pour la préparation d'éphédrine et de composés alcaloïdes apparentés